Why Cordlife
Why Cordlife

Cordlife's Cord Blood Release Track Record

Track Record

Total Releases: 71

Track Record

Autologous: 47

Track Record

Allogeneic: 24

Track Record

Cerebral Palsy: 19

Track Record

Thalassaemia Major: 14

Track Record

Autism Spectrum Disorder (ASD): 18

Track Record

Leukaemia: 8

Neuroblastoma: 3

Brain Injury: 2

Hypoxic-Ischemic Encephalopathy: 3

Fanconi Anaemia: 1

Sickle Cell Anaemia: 1

Global Development Delay: 1

Developmental Dyspraxia: 1



The table below features the cord blood releases performed by Cordlife Group Limited and its subsidiaries. As a Group, Cordlife has made cord blood releases, all of which have been used successfully in transplants or cellular therapy. This is the ultimate validation of our cord blood processing and storage capability.

NO RELEASE MEDICAL CONDITION RECIPIENT'S RELATIONSHIP STORAGE TIME (in months) TREATMENT FACILITY
Show all
Cord blood units sent to South Korea were used for two separate infusions for two children (twins).
Some releases may be for the same client but released in different period.
This list shows the cord blood released by Cordlife and subsidiaries to support the treatment of various diseases. This should not be used as a reference for the list of treatable diseases by cord blood stem cells. In addition, banking your baby’s cord blood does not guarantee that the stem cells will provide a cure or be applicable for every situation. The use is ultimately determined by the treating physician.


QR8.1-7-3 DCR No. 2809, Version i, May 2022
Request A Call Back